Brookline Capital Markets Forecasts Genelux Q1 Earnings

Key Points

• Brookline Capital Markets expects Genelux to remain unprofitable throughout 2027, forecasting losses of $0.10 per share in Q1, $0.13 in Q2, $0.16 in Q3 and $0.19 in Q4. The company’s full-year consensus estimate is a loss of $0.80 per share.
• Genelux reported a quarterly loss of $0.21 per share, missing the $0.20-per-share consensus estimate by $0.01.
• Analyst sentiment remains mixed: Genelux has a consensus “Moderate Buy” rating and an $18 target price, while its shares recently traded at $2.60, near the bottom of their $2.29–$8.53 one-year range.

Genelux Corporation (NASDAQ:GNLX - Free Report) - Investment analysts at Brookline Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for Genelux in a research report issued to clients and investors on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will post earnings per share of ($0.10) for the quarter. The consensus estimate for Genelux's current full-year earnings is ($0.80) per share. Brookline Capital Markets also issued estimates for Genelux's Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.16) EPS and Q4 2027 earnings at ($0.19) EPS.

Genelux (NASDAQ:GNLX - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01).

Several other research analysts have also commented on GNLX. Benchmark restated a "speculative buy" rating on shares of Genelux in a report on Tuesday. Weiss Ratings reissued a "sell (e+)" rating on shares of Genelux in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Genelux from a "sell" rating to a "strong sell" rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Genelux Stock Performance

Shares of NASDAQ:GNLX opened at $2.60 on Wednesday. The stock has a 50-day simple moving average of $2.88 and a 200-day simple moving average of $2.77. The stock has a market capitalization of $116.58 million, a P/E ratio of -3.02 and a beta of 0.60. Genelux has a 1 year low of $2.29 and a 1 year high of $8.53.

Insider Transactions at Genelux

In related news, Director John W. Smither sold 12,000 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total transaction of $34,920.00. Following the transaction, the director directly owned 91,403 shares of the company's stock, valued at approximately $265,982.73. The trade was a 11.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director John Thomas sold 10,000 shares of the company's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $2.98, for a total value of $29,800.00. Following the completion of the transaction, the director owned 472,784 shares of the company's stock, valued at approximately $1,408,896.32. This represents a 2.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 25,868 shares of company stock valued at $76,120. Insiders own 7.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. purchased a new position in shares of Genelux in the fourth quarter valued at $48,000. GSA Capital Partners LLP purchased a new stake in Genelux during the 2nd quarter worth $35,000. Squarepoint Ops LLC acquired a new position in Genelux in the 4th quarter worth $52,000. Balyasny Asset Management L.P. acquired a new position in Genelux in the 4th quarter worth $94,000. Finally, Align Financial LLC purchased a new position in Genelux in the 4th quarter valued at about $123,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Genelux

Here are the key news stories impacting Genelux this week:

• Positive Sentiment: HC Wainwright modestly improved its Q4 2026 EPS forecast to a loss of $0.19 from $0.20, suggesting slightly better near-term expectations. The firm continues to project positive earnings beginning in FY2028, with estimates of $0.61 per share in FY2028, $1.63 in FY2029 and $2.52 in FY2030. HC Wainwright Genelux earnings estimates
• Neutral Sentiment: Brookline Capital Markets issued quarterly 2027 forecasts ranging from a $0.10-per-share loss in Q1 to a $0.19-per-share loss in Q4. The estimates indicate that Genelux is still expected to remain unprofitable throughout 2027, although the figures provide a new analyst framework for future performance. Brookline Capital Markets Genelux earnings estimates
• Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a $0.21 loss from $0.20 and lowered its FY2027 forecast to a $0.77 loss from $0.75. The firm also cut its longer-term estimates for FY2028, FY2029 and FY2030, including reducing FY2030 EPS to $2.52 from $2.61. These revisions suggest weaker expected earnings and may pressure GNLX stock. HC Wainwright lowers Genelux earnings estimates
• Negative Sentiment: Genelux recently reported a quarterly loss of $0.21 per share, slightly worse than the $0.20 analyst consensus. Continued losses, combined with the company’s negative price-to-earnings ratio and lack of near-term profitability, remain headwinds for investors.

About Genelux

Genelux Corporation NASDAQ: GNLX is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company's programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux's lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux's pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source